Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT01937260




Registration number
NCT01937260
Ethics application status
Date submitted
15/07/2013
Date registered
9/09/2013
Date last updated
10/04/2017

Titles & IDs
Public title
Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
Scientific title
An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single-Dose Brodalumab Pharmacokinetics in Subjects With Moderate to Severe Plaque Psoriasis
Secondary ID [1] 0 0
20110184
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Psoriasis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Brodalumab

Experimental: Brodalumab 140mg SC - open label, all subjects receive brodulamab

Experimental: Midazolam (MDZ) 2mg oral, Brodalumab 210mg SC - MDZ 2mg oral (Day 1 and Day 9), Brodalumab 210mg SC (Day 2)


Treatment: Drugs: Brodalumab
Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The Maximum Observed Concentration of Midazolam After a Single Dose of Brodalumab
Timepoint [1] 0 0
Day 1 to day 9
Primary outcome [2] 0 0
The Area Under Drug Concentration Time Curve From Zero to Infinity (AUCinf)
Timepoint [2] 0 0
Day 1 to Day 9
Primary outcome [3] 0 0
The Area Under the Drug-concentration Curve of Midazolam After a Single Dose of Brodalumab From Zero Tot he Last Time of Quantifiable Concentration
Timepoint [3] 0 0
Day 1 to Day 9

Eligibility
Key inclusion criteria
- Subject has had stable moderate to severe plaque psoriasis for at least 6 months

- body mass index (BMI) between = 18.0 and = 38.0 kg/m2

- body weight between = 50 and = 130 kg

- no known history of active tuberculosis
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Female subjects who are lactating/breastfeeding

- History or evidence of clinically significant disorder, condition or disease that, in
the opinion of the investigator or Amgen physician would pose a risk to subject safety
or interfere with the study evaluation, procedures or completion.

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2014
Sample size
Target
Accrual to date
Final
31
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Recruitment hospital [1] 0 0
Research Site - Herston
Recruitment hospital [2] 0 0
Research Site - Adelaide
Recruitment hospital [3] 0 0
Research Site - Prahran
Recruitment postcode(s) [1] 0 0
4006 - Herston
Recruitment postcode(s) [2] 0 0
5000 - Adelaide
Recruitment postcode(s) [3] 0 0
3181 - Prahran
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Texas
Country [4] 0 0
New Zealand
State/province [4] 0 0
Christchurch
Country [5] 0 0
New Zealand
State/province [5] 0 0
Grafton, Auckland

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Bausch Health Americas, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a phase 1, multi-center, open-label, drug-drug interaction (DDI) and PK study in
subjects with moderate to severe plaque psoriasis. It is designed to evaluate the effect of
brodalumab on midazolam PK in addition to assessing single dose PK of brodalumab in subjects
with moderate to severe plaque psoriasis.
Trial website
https://clinicaltrials.gov/ct2/show/NCT01937260
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT01937260